Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2025-07-17 Regulatory Filings
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
Regulatory Filings Classification · 1% confidence The document is a press release announcing a new licensing agreement between Nicox and Kowa for the development and commercialization of a drug (NCX 470). It details the financial terms (upfront payments, milestone payments, and royalties) and the strategic impact on the company's capital structure and debt repayment. This falls under the category of Capital/Financing Update as it describes a significant transaction involving financing and licensing rights.
2025-07-17 English
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470
Earnings Release Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and is dated June 30, 2025. It announces a clinical trial milestone (last patient completed Phase 3 Denali trial) and provides forward-looking statements regarding expected results (mid-August to mid-September 2025) and regulatory submission timelines (H1 2026). This format—a brief, timely announcement of operational or clinical progress, often containing key highlights and future expectations—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, it best fits the 'Earnings Release' category, which often includes operational updates alongside financial highlights, or the general 'Regulatory Filings' (RNS) if it were purely operational. Given the focus on clinical progress and future guidance, ER is a strong fit, although it lacks explicit quarterly financial figures. However, in the context of biotech/pharma, major clinical updates often substitute or accompany ERs. Since it is a formal announcement of a significant event, and not just a notice to publish a report (RPA), it is classified as an Earnings Release (ER) as it communicates key performance/progress indicators to the market. H1 2025
2025-06-30 French
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press Release" and announces a significant operational milestone: the completion of the last patient in the NCX 470 Denali Phase 3 clinical trial, along with expected dates for topline results and NDA submission. This format, focusing on immediate, material operational news rather than comprehensive financial statements (like 10-K or IR) or detailed management commentary (like MDA), strongly indicates an Earnings Release or a general operational update. Since it is a press release announcing clinical trial progress and future regulatory timelines, it fits best under the 'Earnings Release' (ER) category, which often encompasses key operational updates released concurrently with or near earnings periods, or the 'Regulatory Filings' (RNS) as a general announcement. Given the focus on clinical progress and future regulatory steps, it is a primary operational announcement. However, since it is not a formal financial results summary (which would be ER), and it is a specific operational update, it is most accurately classified as a general announcement, which aligns well with the 'Regulatory Filings' (RNS) fallback, or potentially an 'Interim Report' (IR) if it contained interim financials, which it does not. Since it is a press release announcing a major operational event, and it doesn't fit the specific definitions of ER (which usually focuses on financial results highlights), the most appropriate general category for a non-financial, material operational update is RNS, or potentially ER if we interpret 'Earnings Release' broadly to include major operational updates released around earnings time. Given the structure and content (clinical trial update, future milestones), it is a standard corporate announcement. I will classify it as RNS as it is a general regulatory/corporate announcement that doesn't fit the other specific categories like DIV, CAP, or ER (which implies financial results).
2025-06-30 English
Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 27 juin 2025 et désignation d’un mandataire ad hoc
AGM Information Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces the "Convocation à l'Assemblée Générale Ordinaire et Extraordinaire" (Notice of Ordinary and Extraordinary General Meeting) scheduled for June 27, 2025. It details the agenda, the appointment of an *ad hoc* representative to ensure quorum, and instructions for shareholder voting. This content directly relates to the formal meeting of shareholders and the solicitation of votes/information prior to that meeting. While it is an announcement, the core subject matter is the General Meeting and the associated voting procedures, making 'AGM Information' (AGM-R) the most specific fit, as it covers presentations and materials shared during the AGM, and this notice is the primary precursor/material for that event. It is not a DEF 14A (Remuneration) or a DVA (Declaration of Voting Results), but the notice itself.
2025-06-06 French
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative
AGM Information Classification · 1% confidence The document is explicitly titled as a "Press Release" and announces the details for the upcoming "Ordinary and Extraordinary Shareholders' Meeting" scheduled for June 27, 2025. It details the agenda, the appointment of an *ad hoc* representative to ensure quorum, and instructions for shareholders on how to vote (proxy, internet, in person). This content directly relates to the formal procedures and materials surrounding a General Meeting, specifically focusing on the notice and logistics rather than the final voting results (DVA) or the full proxy solicitation materials (DEF 14A/PSI). Since it is a notice/announcement regarding the AGM, the most appropriate classification is AGM Information (AGM-R). It is not a full 10-K, an Earnings Release (ER), or a general Regulatory Filing (RNS), as the subject matter is highly specific to the AGM.
2025-06-06 English
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
Earnings Release Classification · 1% confidence The document is explicitly titled "Press Release" and announces specific corporate and clinical development news, including triggering milestone payments from a partner (Kowa) and updating the cash runway forecast. This format, focusing on immediate, material, non-periodic business updates, strongly aligns with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (like 10-K or IR) but rather a summary of key financial/operational events (milestones, cash runway), it fits the definition of an Earnings Release (ER) which covers periodical financial results highlights, even if the primary focus here is a partnership milestone. It is not a Call Transcript (CT) as it lacks Q&A structure, nor is it a formal statutory report. Given the nature of announcing financial triggers and runway updates, ER is the most appropriate specific code, although RNS is a close fallback. H1 2025
2025-05-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.